VSC: Vital Signs Camera Study

Sponsor
Philips Clinical & Medical Affairs Global (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT06140433
Collaborator
(none)
90
1
4

Study Details

Study Description

Brief Summary

This study is a single center, prospective clinical investigation which is balanced for gender, age, Body Mass Index (BMI) and skin color. Simultaneous measurements of PR and RR on study participants will be collected in conditions described in IFU and various suboptimal conditions. The study participants will be recorded with the VSC demo app (together with a compatible camera and computing hardware) and reference devices. PR and RR data to be collected by the VSC demo app, will be post-processed after the clinical investigation and compared with the reference devices. Persons who are willing to participate will be asked to provide their consent.

Primary objective:

• To assess the clinical safety and effectiveness of Pulse Rate (PR) and Respiration Rate (RR) measured with the VSC-MEDlib within the intended use compared to the gold-standard reference devices.

Exploratory objective:

• To assess the clinical safety and effectiveness of Pulse Rate and Respiration Rate measured with the VSC-MEDlib during suboptimal circumstances (outside the scope of the intended use), compared to the gold-standard reference devices.

Condition or Disease Intervention/Treatment Phase
  • Device: VSC-MEDlib
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Vital Signs Camera Study
Anticipated Study Start Date :
Jan 1, 2024
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
May 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: VSC-MEDlib

SaMD: Data collection study. Software to be applied after data collection.

Device: VSC-MEDlib
VSC-MEDlib will be used for post-processing

Outcome Measures

Primary Outcome Measures

  1. Clinical safety and effectiveness VSC-MEDlib according to IFU [2 hours]

    Clinical safety and effectiveness of the non-invasive and contactless measurement RR by the VSC-MEDlib within the intended use.

  2. Clinical safety and effectiveness VSC-MEDlib according to IFU [2 hours]

    Clinical safety and effectiveness of the non-invasive and contactless measurement of PR by the VSC-MEDlib within the intended use.

Other Outcome Measures

  1. Clinical safety and effectiveness VSC-MEDlib during suboptimal conditions [2 hours]

    Safety and clinical effectiveness during suboptimal conditions, in RMSE, availability, and precision of the non-invasive and contactless measurement of RR by the VSCMEDlib.

  2. Clinical safety and effectiveness VSC-MEDlib during suboptimal conditions [2 hours]

    Safety and clinical effectiveness during suboptimal conditions, in RMSE, availability, and precision of the non-invasive and contactless measurement of PR by the VSCMEDlib.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Persons with ASA I or II classification

  • Adult population (age >18 years old)

  • BMI ≥ 18 - ≤ 40 kg/m2

  • Able to intensively exercise for 10 minutes

  • Persons willing to give informed consent

  • Willingness to have vital signs measured by a medical mobile application

  • Willingness to follow study protocol (e.g., put on sunglasses, facial make-up, medical face-mask and sitting still up to 2 minutes)

Exclusion Criteria:
  • Vulnerable populations (e.g., age <18 years old, not able to consent by themselves, or immunecompromised or pregnant women)

  • Cardiac arrhythmias (e.g., Atrial Fibrillation, Supraventricular Tachycardia, Ventricular arrhythmia, regular ectopic beats)

  • Persons present signs of infection

  • Participant has known allergic reactions to make-up and/or make-up remover

  • Persons with positive COVID 19 test in last 14 days

  • Participant who exhibit irregular or excessive movement such as tremors, tics, shaking and/or shivering

  • Participant is Philips employee or their family members residing with this Philips employee.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Philips Clinical & Medical Affairs Global

Investigators

  • Study Director: Murk Westerterp, Integrated Technology Solutions

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Philips Clinical & Medical Affairs Global
ClinicalTrials.gov Identifier:
NCT06140433
Other Study ID Numbers:
  • IPS-200169-VSCstudy
First Posted:
Nov 20, 2023
Last Update Posted:
Nov 20, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 20, 2023